<ENAMEX TYPE="ORGANIZATION">Immunogen Inc.</ENAMEX> said it filed with the <ENAMEX TYPE="ORGANIZATION">Securities and Exchange Commission</ENAMEX> a registration statement proposing an initial public offering of 1.5 million common shares.
The offering will be underwritten by a syndicate represented by <ENAMEX TYPE="ORGANIZATION">Painewebber Inc.</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">Hambrecht & Quist Inc.</ENAMEX> Proceeds are expected to be used for expenditures relating to product research and development, preclinical and clinical testing programs, expansion of manufacturing capacity, working capital and general corporate purposes.
<ENAMEX TYPE="ORGANIZATION">Immunogen</ENAMEX> develops pharmaceuticals for cancer treatment.
